Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Sponsor

Celgene (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT04973280

Collaborator

(none)

187

Enrollment

Location

14.2

Anticipated Duration (Months)

13.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a non-interventional post-authorization safety study (PASS) employing a cross sectional design to evaluate the effectiveness of the additional risk minimization measures (aRMMs) for REBLOZYL. A survey will be used to measure the knowledge and comprehension of the REBLOZYL aRMMs among European Economic Area (EEA) based healthcare professionals (HCPs). The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available, potentially including Austria, Germany, Italy, Norway, Sweden, the Netherlands, Poland, and Spain. Additional EEA countries may be included, as needed, based on commercial availability and reimbursement status.

Condition or Disease	Intervention/Treatment	Phase
Myelodysplastic Syndromes Beta-thalassemia

Study Design

Study Type:

Observational

Actual Enrollment :

187 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA)

Actual Study Start Date :

Jul 26, 2021

Anticipated Primary Completion Date :

Sep 30, 2022

Anticipated Study Completion Date :

Sep 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Healthcare Professionals (HCPs) The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available. A sample of HCPs from EEA countries who manage care for patients with certain haematologic conditions and who may/do prescribe REBLOZYL will be recruited from the target population of HCPs who were sent the REBLOZYL aRMMs in these countries. The final list of countries to be included may include 1) only countries where reimbursement has been sought and gained, 2) a geographically representative sample (e.g., northern, southern, eastern, and western EU Members States to the degree possible based on the first criteria), 3) a mixture of countries with higher and lower REBLOZYL usage, and 4) other feasibility considerations such as the ability to conduct direct-to-HCP non-market research studies.

Arm

Intervention/Treatment

Healthcare Professionals (HCPs)

The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available. A sample of HCPs from EEA countries who manage care for patients with certain haematologic conditions and who may/do prescribe REBLOZYL will be recruited from the target population of HCPs who were sent the REBLOZYL aRMMs in these countries. The final list of countries to be included may include 1) only countries where reimbursement has been sought and gained, 2) a geographically representative sample (e.g., northern, southern, eastern, and western EU Members States to the degree possible based on the first criteria), 3) a mixture of countries with higher and lower REBLOZYL usage, and 4) other feasibility considerations such as the ability to conduct direct-to-HCP non-market research studies.

Outcome Measures

Primary Outcome Measures

Knowledge that although there are no data from the use of REBLOZYL in pregnant women, studies in animals exposed to REBLOZYL have shown reproductive toxicity and embryo-fetal toxicity [Up to 3 months]
Calculated as the percentage of healthcare professionals (HCPs) who answer "True" to question 1A
Knowledge that women of childbearing potential (WCBP) who become pregnant during treatment with REBLOZYL should not continue REBLOZYL treatment even if they receive appropriate monitoring [Up to 3 months]
Calculated as the percentage of HCPs who answer "False" to question 1B
Knowledge that HCPs must counsel WCBP of the potential teratogenic risk of REBLOZYL [Up to 3 months]
Calculated as the percentage of HCPs who answer "True" to question 1C
Knowledge that for WCBP who become pregnant during treatment with REBLOZYL, the pregnancy outcome should be evaluated [Up to 3 months]
Calculated as the percentage of HCPs who answer "False" to question 1D
Knowledge that the use of REBLOZYL is contraindicated during pregnancy and in WCBP who are not using at least 1 highly effective method of contraception [Up to 3 months]
Calculated as the percentage of HCPs who answer "True" to question 1E
Knowledge of what information about contraception methods should be provided when counselling WCBP [Up to 3 months]
Calculated as the percentage of HCPs who answer "WCBP should use at least 1 highly effective method of contraception during treatment with REBLOZYL and for at least 3 months after stopping treatment" to question 2
Knowledge of how many pregnancy tests should be performed for WCBP before they start treatment with REBLOZYL [Up to 3 months]
Calculated as the percentage of HCPs who answer "A single pregnancy test must be performed and medically verified before starting treatment with REBLOZYL" to question 3
Knowledge of the frequency pregnancy tests should be repeated for WCBP who are receiving treatment with REBLOZYL [Up to 3 months]
Calculated as the percentage of HCPs who answer "At suitable intervals and medically verified as negative" to question 4
Knowledge that WCBP should be informed to report a pregnancy that occurs during treatment with REBLOZYL and should receive counselling if they become pregnant [Up to 3 months]
Calculated as the percentage of HCPs who answer "True" to question 5
Knowledge of how long after stopping treatment with REBLOZYL should WCBP be informed to report a pregnancy that occurs and should they receive counselling if they become pregnant [Up to 3 months]
Calculated as the percentage of HCPs who answer "Pregnancies that occur within 3 months after stopping REBLOZYL should be reported and participants should receive counselling" to question 6
Always providing WCBP with the REBLOZYL Patient Card [Up to 3 months]
Calculated as the percentage of HCPs who answer "Yes, always" to providing the REBLOZYL Patient Card to WCBP (question 10-A). The denominator for this variable is the n who answer question 10 (not the n who answer 10-A)
Composite knowledge for all 5 items in the core question set [Up to 3 months]
A composite endpoint calculated as the percentage of HCPs who answer: None of questions 1E, 2, 3, 4, and 10-A correctly; 1 of questions 1E, 2, 3, 4, and 10-A correctly; 2 of questions 1E, 2, 3, 4, and 10-A correctly; 3 of questions 1E, 2, 3, 4, and 10-A correctly; 4 of questions 1E, 2, 3, 4, and 10-A correctly; All 5 of questions 1E, 2, 3, 4, and 10-A correctly

Secondary Outcome Measures

Awareness of the HCP Checklist [Up to 3 months]
Calculated as the percentage of HCPs who answer "Yes" to question 7
Read/reviewed the HCP Checklist [Up to 3 months]
Calculated as the percentage of HCPs who answer "Yes, all of it" or "Yes, some of it" to question 8
Use of the HCP Checklist prior to initiating treatment [Up to 3 months]
Calculated as percentages of HCPs who answer "Always" or "Sometimes" to question 9A
Use of the HCP Checklist at each subsequent administration [Up to 3 months]
Calculated as percentages of HCPs who answer "Always" or "Sometimes" to question 9B
Use of the HCP Checklist for at least 3 months after stopping treatment [Up to 3 months]
Calculated as percentages of HCPs who answer "Always" or "Sometimes" to question 9C
Primary source from which HCPs learned about the appropriate indication, contraindications and precautions for use, and potential risks for REBLOZYL [Up to 3 months]
Calculated as the percentage of HCPs who tick each source in question 11 (for example, percentage of HCPs that ticked the REBLOZYL summary of product characteristics (SmPC), etc.)

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthcare professionals (HCPs) experienced in treatment of haematological diseases who may intend to prescribe REBLOZYL in the participating European countries and were on the target group for dissemination of the additional risk minimization measures (aRMMs).
The HCP provides permission to share their responses in aggregate with European Medicines Agency (EMA) or National Competent Authorities (NCAs), if requested.

Exclusion Criteria:

HCPs who previously participated in the cognitive pre-testing of the survey questionnaires to be used for the study.
HCPs who have been direct employees of the marketing authorization holder (MAH), the EMA, or the study vendor within the past 5 years.